Blueprint Medicines (BPMC) News Today $110.05 +6.10 (+5.87%) Closing price 04:00 PM EasternExtended Trading$112.25 +2.20 (+2.00%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Leerink Partnrs Comments on BPMC FY2027 EarningsBlueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Leerink Partnrs issued their FY2027 earnings estimates for shares of Blueprint Medicines in a research note issued on Tuesday, January 14th. Leerink Partnrs analyst A. Berens expects that the biotechnology company will post earnings of $4.98 pJanuary 16 at 7:47 AM | marketbeat.comInsider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells 2,250 Shares of StockJanuary 16 at 6:34 AM | insidertrades.comAriel Hurley Sells 2,250 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) StockBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) insider Ariel Hurley sold 2,250 shares of the company's stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $100.00, for a total value of $225,000.00. Following the completion of the transaction, the insider now owns 14,967 shares of the company's stock, valued at $1,496,700. The trade was a 13.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.January 15 at 7:34 PM | marketbeat.comInsider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells 5,000 Shares of StockBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $102.28, for a total transaction of $511,400.00. Following the sale, the director now owns 157,557 shares of the company's stock, valued at $16,114,929.96. This trade represents a 3.08 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.January 15 at 7:34 PM | marketbeat.comMixed Prospects for Blueprint Medicines: Hold Rating Maintained Amid Promising Trials and Side Effect ConcernsJanuary 15 at 11:57 AM | markets.businessinsider.comJMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC)JMP Securities reaffirmed a "market outperform" rating and issued a $125.00 price target on shares of Blueprint Medicines in a research note on Wednesday.January 15 at 10:50 AM | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Shares Gap Up - Time to Buy?Blueprint Medicines (NASDAQ:BPMC) Shares Gap Up - Should You Buy?January 15 at 8:09 AM | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Earns "Buy" Rating from Needham & Company LLCJanuary 15 at 3:27 AM | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Receives "Outperform" Rating from WedbushJanuary 14 at 2:45 AM | americanbankingnews.comBlueprint Medicines (BPMC) Receives a Hold from Piper SandlerJanuary 14 at 12:50 AM | markets.businessinsider.comBlueprint Medicines Shares Jump on View That Ayvakit Could Hit $2B in Revenue by 2030January 13, 2025 | marketwatch.comBlueprint Medicines price target lowered to $124 from $135 at WedbushJanuary 13, 2025 | markets.businessinsider.comBlueprint Medicines (NASDAQ:BPMC) Shares Gap Up - Should You Buy?Blueprint Medicines (NASDAQ:BPMC) Shares Gap Up - Should You Buy?January 13, 2025 | marketbeat.comBlueprint Medicines: Promising Growth with Increased Sales Projections and Innovative Pipeline Supports Buy RatingJanuary 13, 2025 | markets.businessinsider.comBlueprint Medicines' (BPMC) Outperform Rating Reiterated at WedbushWedbush reissued an "outperform" rating and issued a $124.00 target price (down previously from $135.00) on shares of Blueprint Medicines in a research report on Monday.January 13, 2025 | marketbeat.comBlueprint Medicines' (BPMC) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Monday.January 13, 2025 | marketbeat.comBlueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued GrowthJanuary 12, 2025 | prnewswire.comDiversified Trust Co Has $647,000 Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)Diversified Trust Co decreased its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 52.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,418 shares of the biotechnology company's stock after selling 8January 11, 2025 | marketbeat.comBarclays Reaffirms Their Hold Rating on Blueprint Medicines (BPMC)January 10, 2025 | markets.businessinsider.comJ.P. Morgan Sticks to Its Buy Rating for Blueprint Medicines (BPMC)January 7, 2025 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Blueprint Medicines (BPMC)January 7, 2025 | markets.businessinsider.comBlueprint Medicines (NASDAQ:BPMC) Stock Price Up 5.7% - Still a Buy?Blueprint Medicines (NASDAQ:BPMC) Trading 5.7% Higher - Here's What HappenedJanuary 7, 2025 | marketbeat.comBlueprint Medicines Builds On Ayvakit While Crafting Its Next Big HitJanuary 7, 2025 | seekingalpha.comPrincipal Financial Group Inc. Has $1.02 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)Principal Financial Group Inc. decreased its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 81.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,038 shares of the biotechJanuary 5, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Given Consensus Rating of "Moderate Buy" by AnalystsBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twenty research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating, twelveJanuary 5, 2025 | marketbeat.comOpco lists five potential biotech targets into JPMorgan conferenceJanuary 3, 2025 | markets.businessinsider.comBlueprint Medicines' (BPMC) Overweight Rating Reaffirmed at StephensStephens restated an "overweight" rating and set a $140.00 target price on shares of Blueprint Medicines in a report on Thursday.January 2, 2025 | marketbeat.comChristina Rossi Sells 2,274 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) StockDecember 21, 2024 | insidertrades.comBlueprint Medicines' SWOT analysis: stock's potential in precision oncologyDecember 20, 2024 | uk.investing.comInsider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) COO Sells 2,274 Shares of StockBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) COO Christina Rossi sold 2,274 shares of the stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $95.91, for a total value of $218,099.34. Following the completion of the sale, the chief operating officer now directly owns 69,383 shares of the company's stock, valued at approximately $6,654,523.53. This represents a 3.17 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.December 20, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers Sells 15,000 SharesBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) Director Jeffrey W. Albers sold 15,000 shares of Blueprint Medicines stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $89.77, for a total transaction of $1,346,550.00. Following the completion of the transaction, the director now directly owns 157,557 shares in the company, valued at approximately $14,143,891.89. This represents a 8.69 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.December 20, 2024 | marketbeat.comJ.P. Morgan’s top Healthcare stocks for 2025December 20, 2024 | msn.comBlueprint Medicines (NASDAQ:BPMC) Trading Down 3.6% - Here's What HappenedBlueprint Medicines (NASDAQ:BPMC) Stock Price Down 3.6% - Should You Sell?December 19, 2024 | marketbeat.comBlueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2024 | prnewswire.comBlueprint Medicines Co. (NASDAQ:BPMC) Insider Ariel Hurley Sells 1,819 SharesDecember 17, 2024 | insidertrades.comBlueprint Medicines Co. (NASDAQ:BPMC) Position Boosted by Geode Capital Management LLCGeode Capital Management LLC boosted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 1.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,480,187 shares of the biotechnology companyDecember 17, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $169,639.94 in StockBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) insider Ariel Hurley sold 1,819 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $93.26, for a total transaction of $169,639.94. Following the completion of the sale, the insider now owns 14,967 shares of the company's stock, valued at approximately $1,395,822.42. This trade represents a 10.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.December 16, 2024 | marketbeat.comBarclays PLC Reduces Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)Barclays PLC lessened its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 27.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 171,196 shares of the biotechnology company's stock after sellinDecember 16, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Sees Large Growth in Short InterestBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) saw a significant increase in short interest in November. As of November 30th, there was short interest totalling 4,190,000 shares, an increase of 7.2% from the November 15th total of 3,910,000 shares. Based on an average daily trading volume, of 628,200 shares, the short-interest ratio is currently 6.7 days.December 15, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by State Street CorpState Street Corp lifted its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 16.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,765,702 shares of the bioDecember 12, 2024 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twenty-one ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have assigneDecember 11, 2024 | marketbeat.comBlueprint Medicines: A Promising Investment with Innovative Treatments and Strong Financial PositionDecember 10, 2024 | markets.businessinsider.comZimmer Partners LP Invests $1.95 Million in Blueprint Medicines Co. (NASDAQ:BPMC)Zimmer Partners LP acquired a new stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 21,100 shares of the bioteDecember 8, 2024 | marketbeat.comCastleark Management LLC Has $3.14 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC)Castleark Management LLC trimmed its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 13.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,990 shares of the biotechnology company's stock afterDecember 8, 2024 | marketbeat.comWellington Management Group LLP Boosts Stake in Blueprint Medicines Co. (NASDAQ:BPMC)Wellington Management Group LLP boosted its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 22.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,964,610 shares of the biotechDecember 8, 2024 | marketbeat.comBlueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual MeetingDecember 7, 2024 | prnewswire.comHolocene Advisors LP Has $1.57 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC)Holocene Advisors LP cut its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 98.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,914 shares of the biotechnology company's stock after selling 926,550 shares during thDecember 7, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stake in Blueprint Medicines Co. (NASDAQ:BPMC)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 24.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 227,911 shares of the biotechnology company's stock after sDecember 6, 2024 | marketbeat.comReadystate Asset Management LP Purchases New Shares in Blueprint Medicines Co. (NASDAQ:BPMC)Readystate Asset Management LP acquired a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 56,500 shares of the biotechnology company's stock, valued at approximately $5,226,000. Readystate ADecember 5, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $45.89 Million Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)Jacobs Levy Equity Management Inc. raised its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 161.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 496,087 shares of the biotechnology company's stDecember 4, 2024 | marketbeat.com Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMC Media Mentions By Week BPMC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BPMC News Sentiment▼0.590.72▲Average Medical News Sentiment BPMC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BPMC Articles This Week▼277▲BPMC Articles Average Week Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TEVA News Today BGNE News Today GMAB News Today VTRS News Today ITCI News Today SMMT News Today MRNA News Today RDY News Today CTLT News Today SRPT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BPMC) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
